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Abstract 
Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality 
in adults worldwide, but its epidemiology varies markedly by region. Whilst in high-
income countries, the predominant burden of CAP is in the elderly and those with 
chronic cardiovascular and pulmonary comorbidity, CAP patients in low-income 
settings are often working age and, in sub-Saharan Africa, frequently HIV-positive. 
Although region-specific aetiological data are limited, they are sufficient to highlight 
major trends: in high-burden settings, tuberculosis (TB) is common cause of acute CAP; 
Gram-negative pathogens such as Klebsiella pneumoniae are regionally important; HIV-
associated opportunistic infections are common but difficult to diagnose. These 
differences in epidemiology and aetiological profile suggest modified approaches to 
diagnosis, severity assessment and empirical antimicrobial therapy of CAP are 
necessary, but tailored, individualised management approaches are constrained by 
limitations in the availability of radiological and laboratory diagnostic services, as well 
as medical expertise. The widespread introduction of the Xpert MTB/RIF platform 
represents a major advance for TB diagnosis, but innovations in rapid diagnostics for 
other opportunistic pathogens are urgently needed. Severity-assessment tools (e.g. 
CURB65) that are used to guide early management decisions in CAP have not been 
widely validated in low-income settings and locally adapted tools are required. The 
optimal approach to initial antimicrobial therapy choices such as the need to provide 
early empirical cover for atypical bacteria and TB remain poorly defined. 
Improvements in supportive care such as correcting hypoxaemia and intravenous fluid 
management represent opportunities for substantial reductions in mortality.  
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1 Introduction 
Pneumonia is a common cause of morbidity and mortality in adults worldwide. Our 
understanding of pneumonia is however largely based on research from high-income 
Western countries. In these settings, the epidemiology of disease, the spectrum of 
causal pathogens and key prognostic factors are well characterised and the approach 
to clinical management is standardised through national management guidelines. 
Clinicians in developing countries are left to decide whether the findings and 
recommendations are applicable in their local context. Is, for example, the spectrum 
pathogens identified in community-acquired pneumonia (CAP) patients in North 
America informative for selecting empirical antibacterial management in Niger? Does a 
CAP severity assessment tool developed in United Kingdom accurately predict 
outcome in Uganda? This narrative review summarises data on the epidemiology and 
aetiology of CAP in developing countries, where available giving priority to recent data, 
and considers how differences in disease within the broader healthcare context of 
resource limitations might impact upon the approach to diagnosis, assessment and 
management. The scope of the review is restricted to CAP in adults and it does not 
discuss the huge burden of childhood pneumonia that is present in many developing 
countries. 
2 What is a developing country? 
There is no universally accepted definition of what constitutes a developing country. 
The term has been used loosely and inconsistently to describe those countries with 
relatively poorer standards of living and economic prosperity. Until 2016, the World 
Bank classified all low- and middle-income countries (LMICs) as the Developing World.1 
Pneumonia in the developing world  Aston 
 5 
Whilst providing a convenient classification for analytical purposes, this ‘developed’ vs. 
‘developing’ dichotomy is out-dated as economic growth in some developing countries 
accelerates rapidly and the Developing World becomes increasingly dissimilar. The 
World Bank now groups countries into four strata based solely on gross national 
income.1 The United Nations classification incorporates measures of human capital 
(e.g. under-five mortality, adult literacy) as well as economic indices. It identifies 48 
least developed countries (LDCs), defined as low-income countries with severe 
structural impediments to sustainable development.2 The list includes all 31 low-
income economies defined by the World Bank with the exception of Zimbabwe: 34 are 
in sub-Saharan Africa with most others in Southeast Asia (e.g. Cambodia, Bangladesh, 
Laos). Whilst still diverse, LDCs share many characteristics including high infant and 
under-five mortality, low adult life expectancy, food insecurity, incomplete access to 
electricity and limited health care expenditure.2 Most LDCs lie within tropical or sub-
tropical regions. The global burden of HIV both in terms of numbers of people living 
with HIV and new HIV infections, disproportionately affects sub-Saharan Africa.3 Many 
LDCs also face a high burden of tuberculosis (TB).4 Detailed understanding of disease 
epidemiology within LDCs is restricted by the paucity of available data. Therefore, 
whilst attempting to maximise use of data from LDCs, this review includes relevant 
data from lower-middle-income countries within sub-Saharan Africa and Southeast 
Asia. For convenience the term low-income country has been used throughout. 
3 Pneumonia epidemiology: A global perspective 
3.1 Incidence and risk factors 
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In high-income countries, increasing age is clearly the dominant risk factor for CAP. In 
the United States, overall incidence in adults is around 2.5 per 1000 person years, 
rising to 6.3 and 16.4 per 1000 person years in adults aged 65 to 79 and 80 years or 
older, respectively.5 In low-income settings, population-level pneumonia incidence 
data are sparse, but the major burden of disease is highlighted by hospital registry 
data in which pneumonia is amongst the commonest reasons for adult 
hospitalisation.6, 7 Interpretation of incidence data is often complicated by variations in 
the source (e.g. hospital registry, community surveillance), the case definition used 
and, if cause-specific, the extent of the microbiological evaluation. In a prospective 
surveillance study of adults in Central Vietnam the incidence of all-cause CAP was 
estimated at 0.81 per 1000 person years, rising to 6.95 per 1000 person years in those 
aged 75 or older.8 By comparison, the incidence of hospitalised pneumococcal 
pneumonia in a study from rural Thailand was relatively low: estimated at 0.31 and 1.5 
per 1000 person years in all adults and those aged 70 or over, respectively.9 In sub-
Saharan Africa, the incidence of CAP is dominated by the effect of HIV which, if 
untreated, is associated with a 17- to 35-fold increase in pneumococcal pneumonia.10, 
11 In a community surveillance study in rural Kenya the incidence of pneumococcal 
acute respiratory infection (defined as a respiratory symptom with fever, hypoxia or 
hospitalisation) was estimated at 5 and 67 cases per 1000 person years in HIV negative 
and positive individuals, respectively.12 In CAP cohorts from the region, HIV prevalence 
of 50 to 75% is typical.13-16  
Malnutrition, household crowding and exposure to indoor air-pollution from domestic 
combustion of biomass fuels may also contribute to the burden of pneumonia in low-
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income countries.17, 18 Risk factors for CAP that are common in many high-income 
countries such as smoking, COPD, congestive heart failure and cerebrovascular 
disease19 presumably pertain in low-income settings and may become more prominent 
as average life expectancies increase.  
The overall effect of alternative dominant drivers of CAP incidence acting upon 
markedly younger populations means that typical CAP patient encountered by 
clinicians differs markedly between high- and low-income settings. Whilst in the 
former, the predominant and increasing burden of hospitalised CAP is in the elderly 
and individuals with chronic cardiovascular or pulmonary comorbidity 20, a major 
burden of hospitalised CAP in many low-income countries is in working-age adults.10  
3.2 Outcome 
Globally, pneumonia is the commonest infectious cause of death, the fourth 
commonest cause of death overall and the second leading cause of life years lost. In 
2015, the Global Burden of Disease Study estimated that lower respiratory tract 
infection (LRTI) caused 2 million adult deaths and an estimated 37 million years of loss 
life.21 In high-income countries, nearly 90% of all LRTI deaths occur in adults over 70. 
By contrast, in sub-Saharan Africa, 46% of all LRTI deaths occur in children under 5 and 
amongst adults, 55% of deaths occur in those under 70, including 22% in adults aged 
15 to 49 years. These marked differences in mortality burden may, in large part, reflect 
differences in population age distributions, but cause-specific, age-standardised 
mortality data is lacking. Amongst CAP cohorts from Africa, however, the typical trend 
of increasing mortality rates with advancing age seen in high-income settings is not 
consistently found.14-16, 22 
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Within individual CAP cohorts, the observed mortality rate varies markedly with 
disease severity and treatment setting, ranging from <1% to nearly 50%.23 Mortality in 
recently published cohorts from LDCs were: Cambodia, 23%;24 Central African 
Republic, 16%;24 Senegal, 19%;24 Uganda, 18% 25. Reported mortality rates from 
contemporaneous cohorts in high-income countries were: Australia, 6%,26 Germany, 
14%,20 United States, 2%.5 Differences in patient demographics, comorbidity profile 
and clinical practice, particularly in terms of hospitalisation rates, make meaningful 
comparisons of outcome between CAP cohorts difficult. For example, in a recent US 
study of hospitalised CAP, inpatient mortality was 2% but 65% of patients were 
assessed to have low severity disease.5 By comparison, in a national audit of 154 UK 
hospitals, average inpatient mortality was 17%, but the proportion with low severity 
disease was considerably lower at 40%.27 Sow et al recruited contemporary CAP 
cohorts in France and Guinea using an identical case definition that excluded patients 
with HIV and TB: despite being considerably older (mean age 62 vs. 38 years) and 
having a higher burden of comorbid disease, mortality was not significantly higher in 
the French cohort (8% vs. 6%).28  
In high-income countries only around half of deaths that occur in the three months 
following an episode of CAP are directly attributable to pneumonia.29 The risk of death 
in CAP patients remains elevated for at least one year compared to individuals 
hospitalised for other conditions, with much of the excess mortality risk being related 
to decompensation of underlying cardiovascular disease. 30 Neither the nature of 
mortality following CAP (i.e. pneumonia related or non-pneumonia related) nor the 
impact of CAP on long term survival is described in low-income countries.  
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4 Pneumonia aetiology 
Initial antimicrobial therapy for CAP is almost always empirical; selecting an 
appropriate regimen therefore requires knowledge of the spectrum of organisms 
implicated in CAP locally. The differences in climate, geography and social conditions 
between high-income countries in temperate regions and low-income countries in 
tropical regions are likely to influence the prevailing aetiological profile of CAP.31 
4.1 Streptococcus pneumoniae 
For most low-income countries, Streptococcus pneumoniae is amongst the commonest 
cause of CAP, typically identified in around one-quarter of all cases.16, 32, 33 The true 
burden of disease may however be considerably higher since most aetiological studies 
employ only relatively insensitive diagnostic modalities (e.g. sputum Gram stain and 
culture).34 Reduced in vitro susceptibility to both -lactams and macrolides is 
widespread in S. pneumoniae isolates and very common in sub-Saharan Africa and 
Southeast Asia.35, 36 
4.2 Atypical bacterial pathogens 
There are limited data on the burden so-called atypical bacterial infections (i.e. 
Legionella spp., Mycoplasma pneumoniae, Chlamydophila spp.) in low-income 
countries. Recent CAP cohorts from Kenya and South Africa identified legionellosis by 
commercial urinary antigen test in 9% and 2% of patients, respectively.37, 38 
Geographical variations in the prevailing species and serogroups of Legionella may 
reduce the effective sensitivity of urinary antigen testing which is specific for L. 
pneumophila serogroup 1.39 In a recent CAP cohort from rural Thailand, legionellosis 
was identified in 5% of patients and all cases were caused by L. longbeachae.40 
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The apparent burden of Mycoplasma and Chlamydophila infection depends on the 
diagnostic assays used. The few available African studies are largely based on 
serological assays (e.g. ELISA, immunofluorescence, complement fixation).13, 16, 41 A 
high prevalence of Mycoplasma pneumoniae with high rates of macrolide resistance 
has been observed in some middle-income Asian countries,32 but data from low-
income countries are lacking. 
4.3 Gram-negative bacteria 
The burden, spectrum and relative predominance of Gram-negative pathogens in CAP 
varies considerably by geographic region. Haemophilus influenzae remains a common 
cause of CAP and the prevalence of -lactam resistance is increasing.35 In South Africa 
and some Asian countries Klebsiella pneumoniae is a common cause of severe 
bacteraemic CAP, in some cohorts displacing S. pneumoniae as the commonest 
bacterial cause.42, 43 Acinetobacter baumannii – typically associated with noscomial 
pneumonia in high-income countries – has also been identified in as a cause of severe 
CAP in tropical settings.44 Burkholderia pseudomallei, the causative agent of 
melioidosis, is endemic in much of Southeast Asia, and commonly presents as an acute 
pneumonic illness.45 
4.4 Tuberculosis 
The global burden of TB rests disproportionately heavily on low-income countries. TB 
incidence in the WHO African and Southeast Asian regions is 275 and 246 cases per 
100,000, respectively and 86% of global TB deaths occur in these regions.4 Whilst TB 
case finding programmes have largely focused on individuals with prolonged 
respiratory symptoms (usually cough for more than two weeks),46 TB is a frequent 
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cause of acute CAP in high burden settings. In a prospective cohort from Cambodia, TB 
was the commonest cause of acute pneumonia amongst older children and adults, 
accounting for a 26% of all radiographic pneumonia and 55% of cavitatory 
pneumonia.33 Similarly in sub-Saharan Africa, in CAP cohorts where systematic testing 
has been performed, up to 25% of all adult CAP is attributable to TB.13, 16, 24 
4.5 Respiratory viruses 
The increasing availability of sensitive molecular diagnostic tests has highlighted the 
high prevalence of respiratory viruses amongst CAP in high-income countries.5, 26 
Community surveillance of severe-acute respiratory illness in sub-Saharan Africa has 
demonstrated the high burden of circulating respiratory viral pathogens including 
influenza, rhinovirus, respiratory syncytial virus and adenovirus.12 Influenza, in 
particular, is a common cause of hospitalised LRTI.12 The seasonality that characterises 
transmission in temperate climates is often not evident in tropical settings. The weak 
public health and diagnostic laboratory infrastructure, and the close proximity of 
human populations to animal reservoirs, present in many low-income settings renders 
them vulnerable to the emergence and propagation of novel respiratory pathogens. 
5 Pneumonia in the context of HIV 
Respiratory infections are a leading cause of morbidity and mortality in patients living 
with HIV.47 The sequence of pulmonary complications of HIV-infection parallels the 
depletion of CD4 cells.48 Bacterial pneumonia and TB are common even when CD4 
counts are well preserved whilst opportunistic infections, of which Pneumocystis 
jirovecii pneumonia (PCP) is most common, are generally only seen when CD4 counts 
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fall below 200 cells/mL. Most studies of HIV-associated respiratory infections have 
focused on specific aetiologies rather than systematically describing the full spectrum 
of pathogens and therefore there is no consensus on the optimal diagnostic 
algorithm.47 In high-income settings, pneumonia in HIV-infected patients is usually 
regarded separately to CAP in other patients; management is individualised and there 
is often early recourse to invasive investigation. In high burden settings where up to 
three-quarters of all hospitalised CAP patients are HIV-positive, the challenge for local 
CAP guidelines is to provide appropriate recommendations for this complicated group 
of patients using only basic diagnostic facilities. 
The profile of HIV-associated pulmonary infections varies considerably by region. 47, 49 
In high-income countries, bacterial infection, in particular Streptococcus pneumoniae, 
is the commonest cause of CAP in HIV-positive adults overall, whilst PCP is the 
commonest opportunistic infection in those with advanced disease.50 Globally, TB is 
the most important HIV-associated opportunistic infection and is the leading cause of 
HIV-associated mortality.4 Mycobacterium tuberculosis is frequently amongst the most 
commonly identified organism in CAP cohorts from sub-Saharan Africa and high TB 
burden settings in Southeast Asia.13, 24, 33 In certain regions of South Africa, 42% of all 
hospitalised HIV-positive patients with cough have microbiologically-confirmed TB.51 
Historically the burden of PCP in low-income settings was thought to be low,52 but 
recent bronchoscopy studies from African and Asian centres have reported PCP 
prevalence amongst HIV-infected patients with pneumonia of 18 to 44%.22, 53, 54 
Other less common causes of pneumonia may be regionally important. Invasive 
nontyphoidal Salmonella infection is the commonest causes of bacteraemic illness in 
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HIV-positive patients in sub-Saharan Africa and up to 10% present with an apparent 
pneumonic presentation.55 Endemic fungi are common in HIV-infected patients living 
in high burden regions.47 Penicillium marneffei, the causative agent of penicilliosis, is 
endemic throughout much of Southeast Asia and often presents as an acute severe 
pneumonic illness that is clinically indistinguishable from other causes of CAP.31 
Cryptococcosis and histoplasmosis also each account for more than 10% of acute 
pneumonic presentations in HIV-infected patients in endemic areas.31, 56 Non-infective 
complications of HIV (e.g. pulmonary Kaposi’s sarcoma) may masquerade as infections 
and should be consider in the differential diagnosis of acute pneumonic illnesses.22, 47  
6 Healthcare system context 
CAP management guidelines developed in high-income countries assume levels of 
resource in terms of the availability of drugs, equipment, laboratory diagnostics and 
personnel that are absent in most low-income settings.57 In low-income countries 
healthcare services are typically organised in a three-tiered system consisting of 
community health centres, district hospitals and regional central hospitals. In 
community facilities - where the majority of patients are managed - initial assessment 
is made by first level health care workers who may, for example, not have been trained 
to perform chest auscultation.58 Diagnostic tests are typically limited to point-of-care 
HIV and malaria antigens tests, and sputum smear microscopy for acid-fast bacilli 
(AFB). District hospitals are largely staffed by non-medically-qualified general 
multipurpose practitioners such as clinical officers or senior nurses who may lack 
expertise in the management of complicated immunosuppressed patients.58 Whilst 
usually available, chest radiography might be delayed or deliberately restricted for 
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patients with clinical pneumonia who fail to respond to treatment. Specialist physician 
input and laboratory facilities for bacterial and mycobacterial culture and 
Pneumocystis diagnostics are often only available at regional or central hospitals.58 
Whilst the World Health Organization (WHO) list of essential medicines includes all of 
the antimicrobial agents commonly used to treat CAP in high-income settings, many 
healthcare facilities in low-income countries – particularly at community level – 
experience regular and prolonged stock outs.59 Equipment for supportive management 
of patients is also often lacking or deficient.57 Fewer than half of all healthcare facilities 
in sub-Saharan Africa have uninterrupted access to an oxygen source and one-quarter 
have no access at all.60 Even where facilities and resources exist, however, 
transportation costs, user fees for diagnostics or treatment and loss of earnings for 
carers may impose substantial financial barriers that prevent equitable access to 
healthcare provision.  
These constraints define the scope of clinical practice in low-income settings. Clinical 
management guidelines concerning initial assessment, aetiological diagnostics and 
therapeutic options all must be adapted accordingly.58  
7 Diagnosis and assessment  
The three main components of the initial assessment of a patient presenting with 
suspected pneumonia are: confirmation of the diagnosis of pneumonia; assessment of 
disease severity; and identification of the causal pathogen. The approach taken to each 
of these tasks must be adapted in light of the differences in the profile of CAP and the 
available resources.  
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7.1 Defining and diagnosing pneumonia 
The widely accepted diagnostic standard for pneumonia is the presence of a presumed 
new lung parenchymal infiltrate on a plain chest radiograph in the context of a 
compatible clinical presentation.61, 62 Recent studies of computerised tomography 
scanning for patients presenting with suspected CAP have revealed the intrinsic 
limitations of plain chest radiography to accurately identify consolidation.63 These 
limitations are accentuated for immunocompromised patients where the radiographic 
features of infection may be subtle or atypical.64 Poor quality of film production 
coupled with interpretation by junior clinicians with limited radiological training may 
further compromise the accuracy of plain radiography. 
On a practical level, chest radiography might not be immediately available in many 
low-income settings. Currently, WHO advocates a syndromic approach in community 
settings in which pneumonia is diagnosed on the basis of the combination of cough or 
breathing difficulties with two of fever, tachypnoea or chest pain are present.58 The 
accuracy of this clinical case definition for radiographic pneumonia has not been 
systematically evaluated.  
Thoracic ultrasound is an attractive alternative approach for pneumonia diagnosis well 
suited to use in resource-limited settings. Compared to conventional chest 
radiography, it does not require expensive radiation-proof facilities or a consistent 
supply of developer reagents. Portable, battery-operated devices suitable for use in 
community facilities with intermittent electrical power supply are available at 
increasingly affordable prices. With skilled operators, thoracic ultrasound has 
comparable specificity and superior sensitivity to chest radiography to detect lung 
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consolidations.65 Following focused training, the technique can be performed by non-
specialist clinicians with reasonable accuracy.66 Preliminary data also indicate potential 
utility in HIV populations.67  
7.2 Assessing disease severity 
CAP management guidelines from high-income countries recommend that 
management decisions about the setting of patient care and initial antimicrobial 
choice are based on an objective assessment of disease severity made using a 
validated tool.61, 62 CAP severity assessment tools in current use have almost 
universally been derived in populations of non-immunocompromised patients in high-
income settings. It should not be assumed these tools perform accurately in CAP 
populations from low-income countries with very different demographic, comorbidity 
and aetiological profiles. 
The widely used CURB65 score estimates the risk of 30-day mortality in CAP patients 
based on the presence of confusion, urea >7 mmol/L, respiratory rate 30/min, 
systolic blood pressure < 90 mmHg or diastolic blood pressure 60 mmHg and age 65 
years. The derivation cohorts from the UK, New Zealand and Netherlands, however, 
specifically excluded individuals with either HIV or confirmed TB.68 CURB65 has been 
extensively validated in numerous high-income countries and has consistently shown 
good prognostic performance (area under receiving operating characteristic curve 
(AUROC) of 0.80).69 Its relative simplicity compared to other tools such as the 
pneumonia severity index (PSI) make it attractive for use in low-income settings. 
However, the available studies of its accuracy in these populations yield mixed results. 
In a cohort of 280 HIV-infected CAP patients from South Africa, CURB65 score did not 
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correlate with in-hospital mortality for either all CAP overall or specifically 
pneumococcal pneumonia.14 Similarly, CRB65 (the abbreviated version of CURB65 that 
does not require laboratory urea measurement) showed only moderate discriminate 
ability (AUROC: 0.65) for predicting in-patient mortality in a cohort of predominantly 
HIV-positive patients with clinically defined pneumonia in Malawi.15 In a hospitalised 
CAP cohort from Pakistan, however, CURB65 performed accurately with an AUROC of 
0.86.70 
Several studies have attempted to derive alternative locally adapted tools. In a cohort 
from Malawi, Birkhamshaw et al. derived the SWAT-Bp score (based on male sex, 
wasting, inability to stand, pyrexia/hypothermia and low blood pressure) that 
outperformed CRB65 for the prediction of in-patient mortality.15 In a cohort of HIV-
infected patients with suspected pneumonia in Uganda, Koss et al. derived a tool 
based on tachycardia, tachypnoea, hypoxaemia and low CD4 count.25 Whilst neither of 
these novel tools has been adequately validated, these studies serve to indicate that 
there is considerable potential to improve disease severity assessment in low-income 
countries by using alternative tools.  
7.3 Determining microbial aetiology 
7.3.1 General considerations 
Initial antimicrobial therapy for CAP is almost invariably empirical. Determining the 
microbial aetiology of disease not only allows targeted therapy with the resultant 
benefits of optimised clinical efficacy and reduced promotion of antimicrobial 
resistance, but also provides valuable local surveillance data on the temporal trends in 
CAP pathogens.61 CAP management guidelines in high-income countries recommend 
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that both empirical antimicrobial therapy and the extent of investigation to determine 
microbial aetiology are based on severity assessment.61, 62 Patients with severe disease 
initially receive the broadest spectrum treatment to cover all likely pathogens and in 
tandem undergo the most extensive investigation to maximise the chance of later 
targeting therapy. In reality, however, identifying the causal pathogen in CAP is 
challenging: even with extensive investigation in the context of research studies it is 
only achieved in around 50%, and in clinical practice the proportion is much lower.5, 26  
The resource constraints of low-income settings demand that only investigations likely 
to result in a direct and substantial impact on patient management will be sustained. 
For example, the practical clinical value of a test to confirm pneumococcal aetiology is 
uncertain. All empirical CAP treatment regimens include antipneumococcal treatment 
and in low-income settings with high HIV burden, a positive result would not 
necessarily remove the need for continued investigation to exclude co-infections.71 
The utility and cost effectiveness of different diagnostic modalities will also vary by 
region and context. Whilst blood cultures are an expensive and usually fairly 
insensitive diagnostic modality in CAP,61 in a Southeast Asian setting, for example, with 
high rates of bacteraemic Gram-negative disease, the facility might be valuable.33, 43 
Diagnostic tests for use in community-level facilities must require minimal staff 
training and laboratory infrastructure to perform.72 As a complementary strategy to 
strengthening diagnostics at an individual patient-level, maintaining infection 
surveillance programmes based in centres that can support more extensive diagnostics 
(e.g. research facilities), may provide additional, valuable information on local trends 
in prevailing pathogens to inform national treatment guidelines.  
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7.3.2 Tuberculosis diagnostics 
Until recently, the acute diagnosis of TB relied solely on smear microscopy and chest 
radiography. The single-most important advance in TB diagnostics in recent years is 
the development of the automated Cepheid Xpert MTB/RIF platform that can identify 
M. tuberculosis in an unprocessed sputum specimen in less than 2 hours. With an 
overall sensitivity of 88% compared to sputum culture, it offers an incremental 
increase in sensitivity over smear microscopy of approximately 30%.73 In a pragmatic 
clinical trial, Xpert MTB/RIF testing was used effectively by nurses in primary care 
healthcare facilities resulting in increased rates of same-day TB diagnosis and 
treatment initiation compared to a smear-microscopy approach.74 Trials of a new 
battery operated platform (GeneXpert Omni) using next generation Xpert MTB/RIF 
Ultra cartridges with reported sensitivity approaching that of TB culture are currently 
underway.75, 76 
New urine-based diagnostics may help to meet the challenge posed by patients with 
suspected TB who are unable to produce a sputum specimen. The TB Alere Determine 
TB LAM Ag is a point-of-care test assay that detects the mycobacterial cell wall 
glycopeptide lipoarabinomannan (LAM) in urine. Whilst overall, its sensitivity for HIV-
associated TB is only moderate (44%), it does provide improved diagnostic yield over 
sputum smear microscopy alone and is most sensitive in patients with severe disease 
at greatest risk of death (e.g. highly immunocompromised, anaemia, elevated CRP).77 
7.3.3 Pneumocystis jirovecii pneumonia diagnostics 
Until recently, the definitive diagnosis of PCP required the microcscopic examination of 
bronchial lavage or induced sputum specimens for the direct visualisation of 
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Pneumocystis organisms.78 The need for both bronchoscopy and an experienced 
microscopist precluded its use in many low-resource settings, hence the historically 
low-rate of reported PCP in low-income settings.52 New molecular quantitative PCR 
tests have improved sensitivity such that analysis of more easily obtained upper 
respiratory tract specimens (e.g. oral wash, nasopharyngeal aspirate) may be 
sufficiently accurate.79 Recently developed assays that detect circulating fungal cell 
wall components (e.g. 1-3-β-D-glucan) in serum have shown excellent sensitivity for 
detecting PCP in patients with HIV.80 However neither of these two new modalities is 
as yet available in a format that could feasibly be applied in a resource-limited setting 
and new diagnostic options are urgently needed.  
7.3.4 Alternative approaches to inferring aetiology 
CAP guidelines from high-income settings advise that neither clinical nor radiological 
features are sufficiently characteristic to distinguish between pneumonia caused by S. 
pneumoniae and atypical bacterial pathogens.61 In low-income settings with high HIV-
burden, however, the pertinent clinical question is often to differentiate bacterial 
pneumonia from mycobacterial or Pneumocystis pneumonia. Clinical prediction tools 
based on radiological appearance (i.e. diffuse vs. focal infiltrates; presence of 
mediastinal lymphadenopathy) and clinical features (i.e. presence of hypoxaemia) 
have been developed and form the basis of some treatment guidelines despite not 
being widely validated.54, 81 In practice there is considerable overlap in the pattern of 
radiological features seen in patients with PCP and bacterial pneumonia.82 In HIV the 
radiographic features of TB become more variable with increasing degrees of 
immunocompromise.83 Whilst standardised reporting tools and computer-aided 
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systems both reduce the inter-observer variability of interpretation, the inherent 
limitations of the modality still apply.84, 85 Depending upon the local epidemiology, 
Gram-negative pathogens may be an equally likely cause of cavitatory pneumonia as 
TB.33  
Inflammatory biomarkers (e.g. PCT, CRP) have been shown to distinguish bacterial 
from viral pathogens with reasonable accuracy in high-income settings and in children 
in sub-Saharan Africa. In adults with radiographic CAP, PCT levels in bacterial CAP are 
approximately 5 times higher that for TB and 19 times higher that for PCP.50, 53 As yet 
there are no data examining the ability of inflammatory biomarkers to safely define 
antimicrobial therapy in Africa.  
8 Antimicrobial therapy 
8.1 General considerations 
Antimicrobial therapy for CAP is generally defined by national or regional guidelines. In 
resourced-limited settings, both the cost of the drug and the broader implications of 
the treatment regimen in terms of the impact of dosing frequency on nursing time 
need to be considered. As a common indication for antimicrobials, ecological impact 
and likelihood of promoting antimicrobial resistance should be considered.35 
Continued efforts to improve antimicrobial stewardship are needed: a recent survey 
from Viet Nam found that intravenous antibiotics were used in 93% of hospitalised 
CAP patients regardless of the apparent severity of disease.86 Fluoroquinolones have 
potent anti-tuberculous activity and in high TB-burden settings their empirical use may 
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lead to both delayed diagnosis of TB and an increased risk of fluoroquinolone-
resistance.87 
8.2 Severity-stratified antimicrobial selection 
In high-income settings, antimicrobial selection is rationally stratified by disease 
severity and concordance with guidelines is associated with improved outcome.88 In 
severe disease where the deleterious consequences of delayed appropriate treatment 
are potentially greatest, broad-spectrum therapy is used to give immediate cover for 
all probable pathogens including Legionella spp., Staphylococcus aureus, Gram-
negative enteric bacteria and in some cases Pseudomonas. Adopting a similar 
approach in many low-income countries would present difficulties – particularly in high 
HIV and TB burden settings - since empirical therapy for all probable pathogens would 
often have to be broadened to include cover for TB, PCP and in some settings, drug 
resistant Gram-negative enteric bacteria and endemic mycoses. A “step-up” approach 
is typically adopted, whereby non-response on broad-spectrum antibacterials prompts 
sequential addition of other agents, such as antimycobacterials and antifungals. This 
avoids the routine use of complex, expensive and potentially toxic treatments, but may 
miss the opportunity for early gains from aggressive therapy.89  
The WHO Integrated Management of Adolescent and Adult Illness (IMAI) guidelines 
were devised to provide general recommendations for disease management in low-
income countries, particularly for clinicians working in community- or district-level 
healthcare facilities.58 For severe pneumonia, IMAI guidelines recommend ceftriaxone 
plus a macrolide.58 An aminoglycoside may be routinely added in regions with a high 
burden of CAP due to resistant Gram-negative pathogens.81 For HIV-positive patients, 
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high dose co-trimoxazole for treatment of PCP is added for all patients,58 although 
some national guidelines restrict empirical PCP treatment to patients with a suggestive 
chest radiograph or lack of clinical response at 48 hours.81  
In high TB burden settings, the WHO approach to patients with severe CAP and 
negative AFB sputum smears is to first trial broad spectrum antibacterials and if no 
improvement after 3-5 days start TB treatment.46 58 The optimal clinical indicators to 
define non-response are unclear. This approach misses 20% of patients with 
retrospectively culture-proven TB and risks delaying treatment in patients with a high 
risk of early death.74  
9 Supportive management 
Severe pneumonia is often complicated by sepsis – a dysregulated host response to 
infection resulting in organ dysfunction. The key components of sepsis management 
are adequate antimicrobial treatment, source control where relevant, and supportive 
treatment. In high-income settings, a protocolised approach is typically used in which 
intravenous fluids are rapidly administered to correct abnormal physiology such as low 
blood pressure and is associated with reduced mortality.90 In keeping with this 
approach, the WHO IMAI recommends early aggressive intravenous fluids to rapidly 
correct abnormal physiology,58 but the only comparative trial of fluid resuscitation 
approaches in sepsis in a low-income setting was stopped early due to high mortality.91 
Rapid fluid administration may be complicated by acute respiratory distress syndrome 
that in the absence of an intensive care unit may lead to an irretrievable deterioration. 
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Further clinical trials are needed to determine whether an aggressive or conservative 
approach to intravenous fluid administration in sepsis in these settings is preferable.   
Hypoxaemia is a common complication of pneumonia and is independently associated 
with mortality.25 Supplemental oxygen provision in low-income settings is inadequate: 
fewer than half of health care facilities in sub-Saharan Africa have uninterrupted 
access to an oxygen source,60 and in those that do demand invariably outstrips 
supply.92 This is further compounded by the limited availability of pulse oximetry, such 
that the scant oxygen resources that are present may be inappropriately used in 
dyspnoeic but non-hypoxaemic patients.93 In the absence of a piped-oxygen 
infrastructure, oxygen concentrators are often the mainstay of oxygen provision in 
many low-income settings; their effectiveness for correcting hypoxaemia in acutely ill 
adults has not been demonstrated. Whilst the use of non-invasive ventilation in CAP is 
not supported in high-income countries,94 in settings where invasive ventilation is not 
available it is possible it might fill a niche role. 
10 Pneumonia prevention 
Strategies for pneumonia prevention should to also be adapted to the local disease 
profile to achieve maximal benefit. In high-income countries, pneumonia prevention 
strategies focus predominantly on pneumococcal and influenza vaccination of high-risk 
groups and smoking cessation.61 Whilst pneumococcal conjugate vaccine (PCV) is 
known to be effective in HIV-positive patients,95 it remains to be seen whether the 
significant reductions in vaccine-serotype pneumococcal disease observed in adults in 
high-income countries following the introduction of universal infant immunisation with 
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PCV are replicated in high HIV burden settings.96 HIV-infected adults remain an 
important reservoir for carriage of pneumococci even after several years of ART and 
apparent immune reconstitution.97 ART, however, markedly reduces the risk of 
pneumonia in HIV-infected patients and early initiation improves survival.11 The rapid 
roll-out of ART in sub-Saharan Africa has been a huge public health success with more 
than 12.1 million started on treatment,3 but continued efforts are needed to minimise 
patient dropout at each stage of the care cascade from initially seeking HIV testing 
services to HIV diagnosis and linkage to ART programmes and then treatment initiation 
and continued adherence.98 Co-trimoxazole preventative therapy continues to reduce 
the risk of hospitalisation and pneumonia after ART initiation.99 Isoniazid preventative 
therapy also provides an additive benefit over ART, reducing incident TB cases by as 
much as 43% in high burden settings,100 but to date has been widely underutilised in 
sub-Saharan Africa.  
11 Conclusions 
The approach to the assessment and management of CAP must be tailored to local 
settings. This review has highlighted that not only does CAP differ markedly between 
high- and low-income countries in terms of its epidemiology and aetiology (see Box 1), 
most notably with regard to the burdens of HIV and TB, but also in the healthcare 
system context in which it is managed. There is urgent need for improved access for 
basic medical equipment for supportive management and innovations in rapid 
diagnostics both to correctly diagnose pneumonia and to identify the aetiological 
agent. Further research is needed to address key knowledge gaps in disease severity 
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assessment and region-specific aetiological patterns to inform optimal empirical 
treatment strategies with the potential for major reductions in mortality (see Box 2). 
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